Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 8/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13498080 | 0.93 | REN (0.37) | RENSLC6A4KCNH2AKT1SMN1; SMN2 | |
| SCHEMBL2923834 | 0.93 | REN (0.37) | RENSLC6A4KCNH2AKT1SMN1; SMN2 | |
| SCHEMBL3464431 | 0.91 | REN (0.36) | RENKCNH2SMN1; SMN2 | |
| SCHEMBL3464412 | 0.89 | REN (0.37) | RENKCNH2SMN1; SMN2 | |
| SCHEMBL2923764 | 0.89 | REN (0.37) | RENKCNH2SMN1; SMN2 | |
| SCHEMBL2924727 | 0.89 | REN (0.35) | RENSLC6A4HRH3KCNH2 | |
| SCHEMBL3465894 | 0.89 | REN (0.35) | REN | |
| SCHEMBL2925169 | 0.88 | MEN1 (0.35) | RENSLC6A4HRH3KCNH2 | |
| SCHEMBL2925166 | 0.88 | MEN1 (0.35) | RENSLC6A4HRH3KCNH2 | |
| SCHEMBL13498130 | 0.88 | MEN1 (0.35) | RENSLC6A4HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687495-B2 | Substituted piperidines | SPEEDEL EXPERIMENTA AG (CH) | 2010-03-30 | — | — | US | disclosed |
| US-7687495-B2 | Substituted piperidines | SPEEDEL EXPERIMENTA AG (CH) | 2010-03-30 | — | — | US | disclosed |
| US-7687495-B2 | Substituted piperidines | SPEEDEL EXPERIMENTA AG (CH) | 2010-03-30 | — | — | US | disclosed |
| US-20100029628-A1 | 2,4,5-Substituted Piperidines as Renin Inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029628-A1 | 2,4,5-Substituted Piperidines as Renin Inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-1958634-A2 | Substituted piperidines as inhibitors of beta-secretase, cathepsin D, plasmepsin II and/or HIV protease | Speedel Experimenta AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| US-20080171748-A1 | Substituted piperidines | NOVARTIS AG (CH) | 2008-07-17 | — | — | US | disclosed |
| US-20080171748-A1 | Substituted piperidines | NOVARTIS AG (CH) | 2008-07-17 | — | — | US | disclosed |
| US-20080171748-A1 | Substituted piperidines | NOVARTIS AG (CH) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029628-A1 | 2,4,5-Substituted Piperidines as Renin Inhibitors | REN, AGT, AGTR1 | REN 1/4885SLC6A4 811/4885HRH3 1878/4885 |
| US-20080171748-A1 | Substituted piperidines | REN, ACE, AGTR2 | REN 1/4885SLC6A4 425/4885HRH3 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.